Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Drugs & Aging
Erschienen in: Drugs & Aging 1/2018

18.12.2017 | Review Article

Treatment of Older Patients with Acute Lymphoblastic Leukaemia

verfasst von: Nicola Gökbuget

Erschienen in: Drugs & Aging | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

The outcome of adult acute lymphoblastic leukaemia (ALL) has improved significantly during the past decade, mainly due to intensive paediatric-based chemotherapy. Less improvement has been observed in older patients. A significantly lower rate of complete remissions, higher early mortality, higher relapse rate and poorer survival is observed in older compared with younger ALL patients. Most importantly, intensive chemotherapy with or without stem-cell transplantation is less well tolerated in older patients. In addition, there is an increasing incidence of poor prognostic factors with increasing age. Progress has been made with the development of age-adapted, moderately intensive chemotherapy protocols for Ph/BCR-ABL-negative ALL and combinations of tyrosine kinase inhibitors with chemotherapy in Ph/BCR-ABL-positive ALL. Future progress can be expected from new targeted therapies, particularly novel immunotherapies, moderately intensified consolidation strategies and reduced intensity stem-cell transplantation. For this purpose, prospective clinical trials for older patients are urgently needed.
Literatur
1.
2.
Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27(17):2758–65.CrossRefPubMed
3.
Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011;29(5):532–43.CrossRefPubMed
4.
Gokbuget N. Treatment of older patients with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2016;2016(1):573–9.PubMed
5.
6.
Pagano L, Mele L, Casorelli I, Fianchi L, Di FA, Leone G. Acute lymphoblastic leukemia in the elderly. A twelve-year retrospective, single center study. Haematologica. 2000;85(12):1327–9.PubMed
7.
Legrand O, Marie JP, Marjanovic Z, Cadiou M, Blanc C, Ramond S, et al. Prognostic factors in elderly acute lymphoblastic leukaemia. Br J Haematol. 1997;97:596–602.CrossRefPubMed
8.
Thomas X, Olteanu N, Charrin C, Lheritier V, Magaud JP, Fiere D. Acute lymphoblastic leukemia in the elderly: the Edouard Herriot Hospital experience. Am J Hematol. 2001;67(2):73–83.CrossRefPubMed
9.
Chessells JM, Hall E, Prentice HG, Durrant J, Bailey CC, Richards SM. The impact of age on outcome in lymphoblastic leukemia; MRC UKALL X and XA compared: a report from the MRC Paediatric and Adult Working Parties. Leukemia. 1998;12:463–73.CrossRefPubMed
10.
Dinmohamed AG, Szabo A, van der Mark M, Visser O, Sonneveld P, Cornelissen JJ, et al. Improved survival in adult patients with acute lymphoblastic leukemia in the Netherlands: a population-based study on treatment, trial participation and survival. Leukemia. 2016;30(2):310–7.CrossRefPubMed
11.
Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol. 2004;22(22):4626–31.CrossRefPubMed
12.
Mengis C, Aebi S, Tobler A, Dahler W, Fey MF. Assessment of differences in patient populations selected for excluded from participation in clinical phase III acute myelogenous leukemia trials. J Clin Oncol. 2003;21(21):3933–9.CrossRefPubMed
13.
Gökbuget N, Hoelzer D, Arnold R, Böhme A, Bartram CR, Freund M, et al. Subtypes and treatment outcome in adult acute lymphoblastic leukemia (ALL) < > 55 yrs. Hematol J. 2001;1(Suppl. 1):694a.
14.
Chiaretti S, Vitale A, Cazzaniga G, Orlando SM, Silvestri D, Fazi P, et al. Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. Haematologica. 2013;98(11):1702–10.CrossRefPubMedPubMedCentral
15.
Moorman AV, Chilton L, Wilkinson J, Ensor HM, Bown N, Proctor SJ. A population-based cytogenetic study of adults with acute lymphoblastic leukemia. Blood. 2010;115(2):206–14.CrossRefPubMed
16.
Herold T, Baldus CD, Gokbuget N. Ph-like acute lymphoblastic leukemia in older adults. N Engl J Med. 2014;371(23):2235.CrossRefPubMed
17.
Stengel A, Schnittger S, Weissmann S, Kuznia S, Kern W, Kohlmann A, et al. TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis. Blood. 2014;124(2):251–8.CrossRefPubMed
18.
Roberts KG. The biology of Philadelphia chromosome-like ALL. Best Pract Res Clin Haematol. 2017;30(3):212–21.CrossRefPubMed
19.
Herold T, Gokbuget N. Philadelphia-like acute lymphoblastic leukemia in adults. Curr Oncol Rep. 2017;19(5):31.CrossRefPubMed
20.
Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014;371(11):1005–15.CrossRefPubMedPubMedCentral
21.
Roberts KG, Payne-Turner D, McCastlain K, Gu Z, Iacobucci I, Harvey RC, et al. High frequency and poor outcome of Ph-like acute lymphoblastic leukemia in adults. Blood. 2015;126(23):2618.
22.
Roberts KG, Gu Z, Payne-Turner D, McCastlain K, Harvey RC, Chen IM, et al. High frequency and poor outcome of philadelphia chromosome-like acute lymphoblastic leukemia in adults. J Clin Oncol. 2017;35(4):394–401.CrossRefPubMed
23.
Herold T, Schneider S, Metzeler KH, Neumann M, Hartmann L, Roberts KG, et al. Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis. Haematologica. 2017;102(1):130–8.CrossRefPubMedPubMedCentral
24.
Fasan A, Kern W, Nadarajah N, Weber S, Schindela S, Schlenther N, et al. Three steps to the diagnosis of adult Ph-like ALL. Blood. 2015;126(23):2610.
25.
Kozlowski P, Lennmyr E, Ahlberg L, Bernell P, Hulegardh E, Karbach H, et al. Age but not Philadelphia positivity impairs outcome in older/elderly patients with acute lymphoblastic leukemia in Sweden. Eur J Haematol. 2017;99(2):141–9.CrossRefPubMed
26.
Gökbuget N, Hartog MC, Dengler J, Helm.G, Irmer S, Lipp T, et al. First analysis of prognostic factors in elderly Ph/BCR-ABL negative ALL including comorbidity scores: different factors predict mortality and relapse. Onkologie. 2008;31(Suppl. 4):14(V29).
27.
Offidani M, Corvatta L, Malerba L, Marconi M, Catarini M, Centurioni R, et al. Comparison of two regimens for the treatment of elderly patients with acute lymphoblastic leukaemia (ALL). Blood. 2004;104(11):#4490.
28.
Robak T. Acute lymphoblastic leukaemia in elderly patients: biological characteristics and therapeutic approaches. Drugs Aging. 2004;21(12):779–91.CrossRefPubMed
29.
Pallis AG, Wedding U, Lacombe D, Soubeyran P, Wildiers H. Questionnaires and instruments for a multidimensional assessment of the older cancer patient: what clinicians need to know? Eur J Cancer. 2010;46(6):1019–25.CrossRefPubMed
30.
Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol. 2007;25(14):1824–31.CrossRefPubMed
31.
Rodin MB, Mohile SG. A practical approach to geriatric assessment in oncology. J Clin Oncol. 2007;25(14):1936–44.CrossRefPubMed
32.
Winkelmann N, Petersen I, Kiehntopf M, Fricke HJ, Hochhaus A, Wedding U. Results of comprehensive geriatric assessment effect survival in patients with malignant lymphoma. J Cancer Res Clin Oncol. 2011;137(4):733–8.CrossRefPubMed
33.
Tucci A, Ferrari S, Bottelli C, Borlenghi E, Drera M, Rossi G. A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy. Cancer. 2009;115(19):4547–53.CrossRefPubMed
34.
Ingram SS, Seo PH, Martell RE, Clipp EC, Doyle ME, Montana GS, et al. Comprehensive assessment of the elderly cancer patient: the feasibility of self-report methodology. J Clin Oncol. 2002;20(3):770–5.CrossRefPubMed
35.
Hurria A, Gupta S, Zauderer M, Zuckerman EL, Cohen HJ, Muss H, et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer. 2005;104(9):1998–2005.CrossRefPubMed
36.
Hurria A, Cirrincione CT, Muss HB, Kornblith AB, Barry W, Artz AS, et al. Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J Clin Oncol. 2011;29(10):1290–6.CrossRefPubMedPubMedCentral
37.
Giri S, Chi M, Johnson B, McCormick D, Jamy O, Bhatt VR, et al. Secondary acute lymphoblastic leukemia is an independent predictor of poor prognosis. Leuk Res. 2015;39(12):1342–6.CrossRefPubMed
38.
Gökbuget N, Beck J, Brüggemann M, Burmeister T, Buss EC, Frickhofen N, et al. Moderate intensive chemotherapy including CNS-prophylaxis with liposomal cytarabine is feasible and effective in older patients with Ph-negative acute lymphoblastic leukemia (ALL): results of a prospective trial from the German multicenter study group for adult ALL (GMALL). Blood. 2012;120:1493.
39.
Juliusson G, Karlsson K, Hallbook H. Population-based analyses in adult acute lymphoblastic leukemia. Blood. 2010;116(6):1011 (author reply 2).
40.
van Dongen JJ, van der Velden VH, Bruggemann M, Orfao A. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood. 2015;125(26):3996–4009.CrossRefPubMedPubMedCentral
41.
Gokbuget N, Kneba M, Raff T, Trautmann H, Bartram CR, Arnold R, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood. 2012;120(9):1868–76.CrossRefPubMed
42.
43.
Tam-McDevitt J. Polypharmacy, aging, and cancer. Oncology. 2008;22(9):1052–5 (discussion 5, 8, 60).
44.
Puts MT, Monette J, Girre V, Costa-Lima B, Wolfson C, Batist G, et al. Potential medication problems in older newly diagnosed cancer patients in Canada during cancer treatment: a prospective pilot cohort study. Drugs Aging. 2010;27(7):559–72.CrossRefPubMed
45.
Lees J, Chan A. Polypharmacy in elderly patients with cancer: clinical implications and management. Lancet Oncol. 2011;12(13):1249–57.CrossRefPubMed
46.
Cornely OA, Leguay T, Maertens J, Vehreschild M, Anagnostopoulos A, Castagnola C, et al. Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia. J Antimicrob Chemother. 2017;72(12):3501.
47.
Annino L, Ferrari A, Elia L, Rapanotti MC, Romani C, Cedrone M, et al. Clinical and hematological characteristics of adult acute lymphoblastic leukemia (ALL) with ALL-1 gene rearrangements. Blood. 1995;86(S1):173a.
48.
Spath-Schwalbe E, Heil G, Heimpel H. Acute lymphoblastic leukemia in patients over 59 years of age. Experience in a single center over a 10-year period. Ann Hematol. 1994;69(6):291–6.
49.
Gökbuget N, Mueller HJ, Berger U, Boos J, Gerhardt A, Hegge T, et al. Effectivity and toxicity of PEG-L-Asparaginase as part of a multidrug induction regimen in a multicenter trial in adult ALL. Blood. 2000;96(11):3111a.
50.
Sive JI, Buck G, Fielding A, Lazarus HM, Litzow MR, Luger S, et al. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. Br J Haematol. 2012;157(4):463–71.CrossRefPubMedPubMedCentral
51.
O’Brien S, Thomas DA, Ravandi F, Faderl S, Pierce S, Kantarjian H. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer. 2008;113(8):2097–101.CrossRefPubMedPubMedCentral
52.
Gökbuget N, de Wit M, Gerhardt A, Lipp T, Schwartz S, Sommer S, et al. Results of a shortened, dose reduced treatment protocol in elderly patients with acute lymphoblastic leukemia (ALL). Blood. 2000;96(11):3104a.
53.
Toft N, Schmiegelow K, Klausen TW, Birgens H. Adult acute lymphoblastic leukaemia in Denmark. A national population-based retrospective study on acute lymphoblastic leukaemia in Denmark 1998–2008. Br J Haematol. 2012;157(1):97–104.
54.
Geyer MB, Hsu M, Devlin SM, Tallman MS, Douer D, Park JH. Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis. Blood. 2017;129(13):1878–81.CrossRefPubMed
55.
Guru Murthy GS, Venkitachalam R, Mehta P. Trends in survival outcomes of B-lineage acute lymphoblastic leukemia in elderly patients: analysis of Surveillance, Epidemiology, and End Results database. Leuk Lymphoma. 2015;56(8):2296–300.CrossRefPubMed
56.
Ferrari A, Annino L, Crescenzi S, Romani C, Mandelli F. Acute lymphoblastic leukemia in the elderly: results of two different treatment approaches in 49 patients during a 25-year period. Leukemia. 1995;9:1643–7.PubMed
57.
Bassan R, Di BE, Lerede T, Pogliani E, Rossi G, D’Emilio A, et al. Age-adapted moderate-dose induction and flexible outpatient postremission therapy for elderly patients with acute lymphoblastic leukemia. LeukLymphoma. 1996;22(3–4):295–301.
58.
Hunault-Berger M, Leguay T, Thomas X, Legrand O, Huguet F, Bonmati C, et al. A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study. Haematologica. 2011;96(2):245–52.CrossRefPubMed
59.
Sancho JM, Ribera JM, Xicoy B, Morgades M, Oriol A, Tormo M, et al. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. Eur J Haematol. 2007;78(2):102–10.PubMed
60.
Kao S, Xu W, Gupta V, Minden Schuh A, Schimmer A, et al. Outcome of patients aged 60 and over with acute lymphoblastic leukemia (ALL) treated with a modified pediatric protocol. Blood. 2008;112:3962a.
61.
Fathi AT, DeAngelo DJ, Stevenson KE, Kolitz JE, Asch JD, Amrein PC, et al. Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia. Cancer. 2016;122(15):2379–88.
62.
Patel B, Kirkwood AA, Dey A, Marks DI, McMillan AK, Menne TF, et al. Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial. Leukemia. 2017;31(1):58–64.CrossRefPubMed
63.
Taylor PR, Reid MM, Proctor SJ. Acute lymphoblastic leukaemia in the elderly. LeukLymphoma. 1994;13(5–6):373–80.
64.
Delannoy A, Ferrant A, Bosly A, et al. Acute lymphoblastic leukemia in the elderly. Eur J Haematol. 1990;45:90.CrossRefPubMed
65.
Nagura E, Minami S, Nagata K, Morishita Y, Takeyama H, Sao H, et al. Analysis of elderly patients, aged 60 years old or over, with acute lymphoblastic leukemia. Nippon Ronen Igakkai Zasshi. 1999;36(1):52–8.CrossRefPubMed
66.
Onciu M, Lai R, Kantarjian H, Ball G, Smith T, Buesco-Ramos C. Acute lymphoblastic leukemia (ALL) in the elderly—the significance of the philadelphia chromosome. Blood. 2000;96(11):4558.
67.
Kantarjian HM, O’Brien S, Smith T, Estey EH, Beran M, Preti A, et al. Acute lymphocytic leukaemia in the elderly: characteristics and outcome with the vincristine-adriamycin-dexamethasone (VAD) regimen. Br J Haematol. 1994;88:94–100.CrossRefPubMed
68.
Mandelli F, Annino L. Ferrari A, for the GG. ALL in elderly: the GIMEMA trials. Ann Hematol. 1995;70(S2):41a.
69.
Kantarjian HM, O’Brien S, Smith TL, Cortes J, Giles FJ, Beran M, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J ClinOncol. 2000;18(3):547–61.CrossRef
70.
Todeschini G, Tecchio C, Meneghini V, Pizzola G, Krampera M, Ambrosetti A, et al. Acute lymphoblastic leukemia (ALL) in elderly patients receiving intensive treatment. Experience in 26 consecutive patients. Blood. 1996;88 (Suppl 1):170b.
71.
Ribera JM, Garcia O, Oriol A, Gil C, Montesinos P, Bernal T, et al. Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: results of three prospective parallel trials from the PETHEMA group. Leuk Res. 2016;41:12–20.CrossRefPubMed
72.
Delannoy A, Sebban C, Cony-Makhoul P, Cazin B, Cordonnier C, Bouabdallah R, et al. Age-adapted induction treatment of acute lymphoblastic leukemia in the elderly and assessment of maintenance with interferon combined with chemotherapy. A multicentric prospective study in forty patients. Leukemia. 1997;11:1429–34.CrossRefPubMed
73.
Delannoy A, Cazin B, Thomas X, Bouabdallah R, Boiron JM, Huguet F, et al. Treatment of acute lymphoblastic leukemia in the elderly: an evaluation of interferon alpha given as a single agent after complete remission. Leukemia Lymphoma. 2002;43(1):75–81.CrossRefPubMed
74.
Gökbuget N, Leguay T, Hunault M, Al-Nawakil C, Chevallier P, Dombret H, et al. First European chemotherapy schedule for elderly patients with acute lymphoblastic leukemia: promising remission rate and feasible moderate dose intensity consolidation. ASH Annu Meet Abstr. 2008;112(11):304.
75.
Delannoy A, Delabesse E, Lheritier V, Castaigne S, Rigal-Huguet F, Raffoux E, et al. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. Leukemia. 2006;20(9):1526–32.CrossRefPubMed
76.
Vignetti M, Fazi P, Cimino G, Martinelli G, Di RF, Ferrara F, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive acute lymphoblastic leukemia patients without additional chemotherapy: results of the GIMEMA LAL0201-B protocol. Blood. 2007;109(9):3676–8.CrossRefPubMed
77.
Ottmann OG, Wassmann B, Pfeifer H, Giagounidis A, Stelljes M, Duhrsen U, et al. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL). Cancer. 2007;109(10):2068–76.CrossRefPubMed
78.
Foa R, Vitale A, Vignetti M, Meloni G, Guarini A, De Propris MS, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011;118(25):6521–8.CrossRefPubMed
79.
Papayannidis C, Fazi P, Piciocchi A, Di Raimondo F, Pizzolo G, Carella AM, et al. Treating Ph + Acute Lymphoblastic Leukemia (ALL) in the Elderly: the Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse. Blood. 2012;102:2601.
80.
Pfeifer H, Wettner C, Wassmann B, Giagounidis A, Stelljes M, Duehrsen U, et al. Long term follow-up of 121 elderly patients with philadelphia-positive acute lymphoblastic leukaemia (Ph + ALL) treated in prospective GMALL trials supports a greater emphasis on allogeneic SCT as definitive postremission Therapy. Blood. 2012;120:2608.
81.
Ottmann OG, Pfeifer H, Cayuela J-M, Spiekermann K, Beck J, Jung WE, et al. Nilotinib (Tasigna®) and chemotherapy for first-line treatment in elderly patients with de novo philadelphia chromosome/BCR-ABL1 positive acute lymphoblastic leukemia (ALL): a trial of the European working group for adult ALL (EWALL-PH-02). Blood. 2014;124(21):#798.
82.
Rousselot P, Coude MM, Gokbuget N, Gambacorti Passerini C, Hayette S, Cayuela JM, et al. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood. 2016;128(6):774–82.CrossRefPubMedPubMedCentral
83.
Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015;16(15):1547–55.CrossRefPubMedPubMedCentral
84.
Martinelli G, Boissel N, Chevallier P, Ottmann O, Gokbuget N, Topp MS, et al. Complete hematologic and molecular response in adult patients with relapsed/refractory philadelphia chromosome-positive b-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol. 2017:JCO2016693531.
85.
Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740–53.CrossRefPubMedPubMedCentral
86.
Patel SB, Gojo I, Tidwell ML, Sausville EA, Baer MR. Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy. Leukemia Lymphoma. 2011;52(7):1211–4.CrossRefPubMed
87.
Bassan R. Optimal central nervous system prophylaxis in Philadelphia chromosome-positive acute lymphoblastic leukemia: collateral damage in the imatinib era? Leukemia Lymphoma. 2011;52(7):1164–5.CrossRefPubMed
88.
Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, et al. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood. 2017;130(9):1156–64.CrossRefPubMed
89.
Martino R, Giralt S, Caballero MD, Mackinnon S, Corradini P, Fernandez-Aviles F, et al. Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study. Haematologica. 2003;88(5):555–60.PubMed
90.
Arnold R, Massenkeil G, Bornhauser M, Ehninger G, Beelen DW, Fauser AA, et al. Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease. Leukemia. 2002;16(12):2423–8.CrossRefPubMed
91.
Hamaki T, Kami M, Kanda Y, Yuji K, Inamoto Y, Kishi Y, et al. Reduced-intensity stem-cell transplantation for adult acute lymphoblastic leukemia: a retrospective study of 33 patients. Bone Marrow Transpl. 2005;35(6):549–56.CrossRef
92.
Mohty M, Labopin M, Volin L, Gratwohl A, Socie G, Esteve J, et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2010;116(22);4439–43.
93.
Marks DI, Wang T, Perez WS, Antin JH, Copelan E, Gale RP, et al. The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. Blood. 2010;116(3):366–74.CrossRefPubMedPubMedCentral
94.
Ram R, Storb R, Sandmaier BM, Maloney DG, Woolfrey A, Flowers ME, et al. Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia. Haematologica. 2011;96(8):1113–20.CrossRefPubMedPubMedCentral
95.
Wolach O, Stevenson KE, Wadleigh M, DeAngelo DJ, Steensma DP, Ballen KK, et al. Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission. Am J Hematol. 2016;91(8):793–9.
96.
Kantarjian H, Thomas D, Wayne AS, O’Brien S. Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia. J Clin Oncol. 2012;30(31):3876–83.CrossRefPubMedPubMedCentral
97.
Bhojwani D, Pui CH. Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol. 2013;14(6):e205–17.CrossRefPubMed
98.
99.
Gökbuget N, Basara N, Baurmann H, Beck J, Bruggemann M, Diedrich H, et al. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. Blood. 2011;118(13):3504–11.CrossRefPubMed
100.
Dunsmore KP, Devidas M, Linda SB, Borowitz MJ, Winick N, Hunger SP, et al. Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group. J Clin Oncol. 2012;30(22):2753–9.CrossRefPubMedPubMedCentral
101.
O’Brien S, Damon LE, Larson ML, Schiller G, Stock W, Thomas DA, et al. Early signs of tolerability and activity in a phase 2 study of weekly vincristine sulfate liposomal injection (VSLI, MarqiboO“) in adults with philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) in second relapse or progressing following two anti-leukemia treatment lines. ASH Annu Meet Abstr. 2008;112(11):3959.
102.
Thomas DA, O’Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010;28(24):3880–9.CrossRefPubMedPubMedCentral
103.
Maury S, Chevret S, Thomas X, Heim D, Leguay T, Huguet F, et al. Addition of rituximab improves the outcome of adult patients with CD20-positive, Ph-negative, B-Cell precursor acute lymphoblastic leukemia (BCP-ALL): results of the randomized Graall-R 2005 study. Blood. 2015;126:1 (abstract).
104.
Goebeler ME, Bargou R. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy. Leuk Lymphoma. 2016;57(5):1021–32.CrossRefPubMed
105.
Topp MS, Gokbuget N, Stein AS, Zugmaier G, O’Brien S, Bargou RC, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57–66.CrossRefPubMed
106.
Kantarjian H, Stein A, Gokbuget N, Fielding AK, Schuh AC, Ribera JM, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836–47.CrossRefPubMed
107.
Kantarjian HM, Stein AS, Bargou RC, Grande Garcia C, Larson RA, Stelljes M, et al. Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: results from 2 phase 2 studies. Cancer. 2016;122(14):2178–85.CrossRefPubMed
108.
Gökbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, et al. Long-term outcomes after blinatumomab treatment: follow-up of a phase 2 study in patients (Pts) with minimal residual disease (MRD) positive B-cell precursor acute lymphoblastic leukemia (ALL). Blood. 2015;126:23.
109.
Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012;13(4):403–11.CrossRefPubMed
110.
Thota S, Advani A. Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia. Eur J Haematol. 2017;98(5):425–34.CrossRefPubMed
111.
Geyer MB, Brentjens RJ. Review: current clinical applications of chimeric antigen receptor (CAR) modified T cells. Cytotherapy. 2016;18(11):1393–409.CrossRefPubMedPubMedCentral
112.
Park JH, Riviere I, Wang X, Bernal Y, Purdon T, Halton E, et al. Implications of minimal residual disease negative complete remission (MRD-CR) and allogeneic stem cell transplant on safety and clinical outcome of CD19-targeted 19-28z CAR modified T Cells in adult patients with relapsed, refractory B-Cell ALL. Blood. 2015;126:682.
113.
Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, et al. CD19 CAR-T cells of defined CD4 + :CD8 + composition in adult B cell ALL patients. J Clin Invest. 2016;126(6):2123–38.CrossRefPubMedPubMedCentral
114.
Frey NV, Shaw PA, Hexner EO, Gill S, Marcucci K, Luger SM, et al. Optimizing chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL). J Clin Oncol. 2016;34 (abstract 7002).
115.
Frey NV, Porter DL. Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Program. 2016;2016(1):567–72.
116.
Sasaki K, Jabbour EJ, O’Brien SM, Ravandi F, Thomas DA, Garcia-Manero G, et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients with acute lymphoblastic leukemia (ALL): interim result of a phase II clinical trial. Blood. 2016;128(22):588.
117.
Gökbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, et al. Long-term outcomes after blinatumomab treatment: follow-up of a phase 2 study in patients (Pts) with minimal residual disease (MRD) positive B-cell precursor acute lymphoblastic leukemia. Blood. 2015;126(23):680.
Metadaten
Titel
Treatment of Older Patients with Acute Lymphoblastic Leukaemia
verfasst von
Nicola Gökbuget
Publikationsdatum
18.12.2017
Verlag
Springer International Publishing
Erschienen in
Drugs & Aging / Ausgabe 1/2018
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-017-0503-5

Weitere Artikel der Ausgabe 1/2018

Drugs & Aging 1/2018 Zur Ausgabe

Original Research Article

The EURO-FORTA (Fit fOR The Aged) List: International Consensus Validation of a Clinical Tool for Improved Drug Treatment in Older People

Original Research Article

Associations between the Drug Burden Index, Potentially Inappropriate Medications and Quality of Life in Residential Aged Care

Therapy in Practice

Incontinence-Associated Dermatitis: Pathogenesis, Contributing Factors, Prevention and Management Options

Original Research Article

Drug Burden and its Association with Falls Among Older Adults in New Zealand: A National Population Cross-Sectional Study

Systematic Review

Brain Over Bladder: A Systematic Review of Dual Cholinesterase Inhibitor and Urinary Anticholinergic Use

Systematic Review

Tools for Assessment of the Appropriateness of Prescribing and Association with Patient-Related Outcomes: A Systematic Review

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise